Perspective Therapeutics, Inc. (CATX)
2.81
+0.04
(+1.44%)
USD |
NYAM |
Sep 11, 16:00
2.815
0.00 (0.00%)
After-Hours: 20:00
Perspective Therapeutics Enterprise Value : 87.67M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 87.67M |
| September 10, 2026 | 83.11M |
| September 09, 2026 | 108.20M |
| September 08, 2026 | 123.04M |
| September 04, 2026 | 124.18M |
| September 03, 2026 | 123.04M |
| September 02, 2026 | 120.75M |
| September 01, 2026 | 120.75M |
| August 31, 2026 | 127.60M |
| August 28, 2026 | 121.89M |
| August 27, 2026 | 129.88M |
| August 26, 2026 | 127.60M |
| August 25, 2026 | 142.43M |
| August 24, 2026 | 131.02M |
| August 21, 2026 | 143.57M |
| August 20, 2026 | 133.30M |
| August 19, 2026 | 164.11M |
| August 18, 2026 | 133.30M |
| August 17, 2026 | 134.44M |
| August 14, 2026 | 132.16M |
| August 13, 2026 | 120.75M |
| August 12, 2026 | 139.01M |
| August 11, 2026 | 129.88M |
| August 10, 2026 | 109.35M |
| August 07, 2026 | 109.35M |
| Date | Value |
|---|---|
| August 06, 2026 | 105.92M |
| August 05, 2026 | 102.50M |
| August 04, 2026 | 109.35M |
| August 03, 2026 | 110.49M |
| July 31, 2026 | 99.08M |
| July 30, 2026 | 108.20M |
| July 29, 2026 | 94.51M |
| July 28, 2026 | 94.51M |
| July 27, 2026 | 88.81M |
| July 24, 2026 | 99.08M |
| July 23, 2026 | 103.64M |
| July 22, 2026 | 105.92M |
| July 21, 2026 | 107.06M |
| July 20, 2026 | 100.22M |
| July 17, 2026 | 108.20M |
| July 16, 2026 | 103.64M |
| July 15, 2026 | 134.44M |
| July 14, 2026 | 115.05M |
| July 13, 2026 | 119.61M |
| July 10, 2026 | 110.49M |
| July 09, 2026 | 128.74M |
| July 08, 2026 | 153.84M |
| July 07, 2026 | 157.26M |
| July 06, 2026 | 178.94M |
| July 02, 2026 | 181.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 266.01M |
| MiMedx Group, Inc. | 547.33M |
| ABVC BioPharma, Inc. | 30.03M |
| Enovis Corp. | 2.470B |
| Edwards Lifesciences Corp. | 45.20B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.98M |
| Revenue (Quarterly) | 0.081M |
| Total Expenses (Quarterly) | 27.06M |
| EPS Diluted (Quarterly) | -0.222 |
| Gross Profit Margin (Quarterly) | -1.31K% |
| Profit Margin (Quarterly) | -33.31K% |
| Earnings Yield | -47.28% |
| Normalized Earnings Yield | -43.93 |